Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2000-11-01
2003-04-15
Russel, Jeffrey E. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S016700, C514S475000, C514S478000, C514S588000, C530S300000, C530S329000, C549S332000, C560S157000, C564S032000
Reexamination Certificate
active
06548477
ABSTRACT:
BACKGROUND OF THE INVENTION
Angiogenesis is the fundamental process by which new blood vessels are formed and is essential to a variety of normal body activities (such as reproduction, development and wound repair). Although the process is not completely understood, it is believed to involve a complex interplay of molecules which both stimulate and inhibit the growth of endothelial cells, the primary cells of the capillary blood vessels. Under normal conditions, these molecules appear to maintain the microvasculature in a quiescent state (i.e., one of no capillary growth) for prolonged periods which may last for as long as weeks or in some cases, decades. When necessary, however, (such as during wound repair), these same cells can undergo rapid proliferation and turnover within a 5 day period (Folkman, J. and Shing, Y.,
Journal of Biological Chemistry
, 267(16): 10931-10934, and Folkman, J. and Klagsbrun, M. (1987)
Science
, 235: 442-447).
Although angiogenesis is a highly regulated process under normal conditions, many diseases (characterized as “angiogenic diseases”) are driven by persistent unregulated angiogenesis. Otherwise stated, unregulated angiogenesis may either cause a particular disease directly or exacerbate an existing pathological condition. For example, ocular neovacularization has been implicated as the most common cause of blindness and dominates approximately 20 eye diseases. In certain existing conditions such as arthritis, newly formed capillary blood vessels invade the joints and destroy cartilage. In diabetes, new capillaries formed in the retina invade the vitreous, bleed, and cause blindness. Growth and metastasis of solid tumors are also angiogenesis-dependent (Folkman, J. (1986)
Cancer Research
46: 467-473 and Folkman, J. (1989)
Journal of the National Cancer Institute
82: 4-6). It has been shown, for example, that tumors which enlarge to greater than 2 mm, must obtain their own blood supply and do so by inducing the growth of new capillary blood vessels. Once these new blood vessels become embedded in the tumor, they provide a means for tumor cells to enter the circulation and metastasize to distant sites, such as the liver, lung or bone (Weidner, N., et al. (1991)
The New England Journal of Medicine
324(1):1-8).
Fumagillin is a known compound which has been used as an antimicrobial and antiprotozoal. Its physicochemical properties and method of production are well known (U.S. Pat. No. 2,803,586 and
Proc. Nat. Acad. Sci. USA
(1962) 48:733-735). Fumagillin and certain types of Fumagillin analogs have also been reported to exhibit antiangiogenic activity. However, the use of such inhibitors (e.g., TNP-470) may be limited by their rapid metabolic degradation, erratic blood levels, and by dose-limiting central nervous system (CNS) side effects.
Accordingly, there is still a need for angiogenesis inhibitors which are more potent, less neurotoxic, more stable, and/or have longer serum half-lives.
SUMMARY OF THE INVENTION
The present invention provides angiogenesis inhibitor compounds which comprise a core, e.g., a Fumagillin core, that is believed to inhibit methionine aminopeptidase 2 (MetAP-2), coupled to a peptide. The present invention is based, at least in part, on the discovery that coupling the MetAP-2 inhibitory core to a peptide prevents the metabolic degradation of the angiogenesis inhibitor compound to ensure a superior pharmacokinetic profile and limits CNS side effects by altering the ability of the angiogenesis inhibitor compound to cross the blood brain barrier. The present invention is also based, at least in part, on the discovery that coupling the MetAP-2 inhibitory core to a peptide comprising a site-directed sequence allows for a cell specific delivery of the angiogenesis inhibitor compound and limits the toxicity of the angiogenesis inhibitor compound.
Accordingly, the present invention is directed to angiogenesis inhibitor compounds of Formula I,
where A is a MetAP-2 inhibitory core and W is O or NR. In one embodiment, Z is —C(O)— or -alkylene-C(O)—and P is NHR, OR or a peptide consisting of one to about one hundred amino acid residues connected at the N-terminus to Z. In this embodiment, Q is hydrogen, linear, branched or cyclic alkyl or aryl, provided that when P is —OR, Q is not hydrogen.
In another embodiment, Z is -alkylene-O— or -alkylene-N(R)—and P is hydrogen or a peptide consisting of from one to about one hundred amino acid residues connected to Z at the carboxyl terminus. In this embodiment, Q is hydrogen, linear, branched or cyclic alkyl or aryl, provided that when P is hydrogen, Q is not hydrogen.
In the angiogenesis inhibitor compounds of Formula I, each R is, independently, hydrogen or alkyl.
In another aspect, the invention features pharmaceutical compositions comprising the angiogenesis inhibitor compounds of Formula I and a pharmaceutically acceptable carrier.
In yet another aspect, the invention features a method of treating an angiogenic disease, e.g., cancer, in a subject. The method includes administering to the subject a therapeutically effective amount of one or more angiogenesis inhibitor compounds of Formula I.
Other features and advantages of the invention will be apparent from the following detailed description and claims.
REFERENCES:
patent: 4703107 (1987-10-01), Monsigny et al.
patent: 5135919 (1992-08-01), Folkman et al.
patent: 5180738 (1993-01-01), Kishimoto et al.
patent: 5290807 (1994-03-01), Folkman et al.
patent: 5648382 (1997-07-01), Billington et al.
patent: 5698586 (1997-12-01), Kishimoto et al.
patent: 5767293 (1998-06-01), Oku et al.
patent: 5789405 (1998-08-01), Oku et al.
patent: 6017954 (2000-01-01), Folkman et al.
patent: 0 354 767 (1990-02-01), None
patent: 0 357 061 (1990-03-01), None
patent: 0 359 036 (1990-03-01), None
patent: 0 387 650 (1990-09-01), None
patent: 0 415 294 (1991-03-01), None
patent: 0 415 294 (1991-03-01), None
patent: WO 98/13059 (1998-04-01), None
patent: WO 98/56372 (1998-12-01), None
patent: WO 9959986 (1999-11-01), None
patent: WO 9961432 (1999-12-01), None
patent: WO 00/64486 (2000-11-01), None
patent: WO 00/64486 (2000-11-01), None
patent: WO 0069472 (2000-11-01), None
Denmeade SR, et al. “Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.”Cancer Res. Jun. 15, 1998; 58(12):2537-40.
Griffith EC, et al. “Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2.”Proc Natl Acad Sci U S A. Dec. 22, 1998;95(26):15183-8.
Griffith EC, et al. “Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin”.Chem Biol. Jun. 1997;4(6):461-71.
Han CK, et al. “Design and synthesis of highly potent fumagillin analogues from homology modeling for a human MetAP-2.”Bioorg Med Chem Lett. Jan 3, 2000;10(1):39-43.
Landquist, JK “Some Degradation Products of Fumagillin”J. Chem. Soc. 1956: 4237-4245.
Tarbell et al. “The Structure of Fumagillin” Feb. 20, 1960; 82:1005-1007.
Liu S, et al. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science. Nov. 13, 1998;282(5392):1324-7.
Sin N, et al. “The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2.”Proc Natl Acad Sci U S A. Jun. 10, 1997;94(12):6099-103.
Timar F, et al. “The antiproliferative action of a melphalan hexapeptide with collagenase-cleavable site.”Cancer Chemother Pharmacol. 1998;41(4):292-8.
Turk BE, et al. “Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells.”Chem Biol. Nov. 1999;6(11):823-33.
De Marre, A. et al., “Synthesis and evaluation of macromolecular prodrugs of mitomycin C,”Journal of Controlled Release36(1/2):87-7 (Sep. 1995).
Nichifor, M. et al., “Chemical and Enzymatic hydrolysis of dipeptide derivatives of 5-fluorouracil,”Journal of Controlled Release47:271-281 (1997).
Birktoft Jens J.
Cook Charles Michael
Lee Lily
Olson Gary L.
Self Christopher
DeConti, Jr. Giulio A.
Laccotripe Zacharakis Maria
Lahive & Cockfield LLP
Praecis Pharmaceuticals Inc.
Russel Jeffrey E.
LandOfFree
Therapeutic agents and methods of use thereof for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agents and methods of use thereof for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents and methods of use thereof for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3046849